Comprehensive approaches to managing delirium in patients with advanced cancer

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 105-112

  Kang, Jung Hun ^a,b   Shin, Seong Hoon ^a,c   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Gyeongsang National University   (South Korea)

^c Kosin University   (South Korea)

Author keywords

Advanced cancer; Delirium

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CORTICOSTEROID; DONEPEZIL; HALOPERIDOL; HYDROCORTISONE; INTERLEUKIN 6; LEVOMEPROMAZINE; LORAZEPAM; METHYLPHENIDATE; MIDAZOLAM; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; OPIATE; PHENOBARBITAL; PLACEBO; PROPOFOL; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; AGITATION; ATTENTION DISTURBANCE; BINDING AFFINITY; CANCER PALLIATIVE THERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CONSERVATIVE TREATMENT; CYTOKINE RELEASE; DELIRIUM; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DSM-III; DSM-III-R; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INCIDENCE; INFLAMMATION; LOW DRUG DOSE; LUNG DISEASE; MEDICAL LITERATURE; MEMORIAL DELIRIUM ASSESSMENT SCALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PERCEPTION DISORDER; POLYPHARMACY; PREVALENCE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP WAKING CYCLE; TREATMENT OUTCOME;

DELIRIUM; HUMANS; NEOPLASMS;

EID: 84869087661     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.08.001     Document Type: Review

References (103)

1. Bruera E., Bush S.H., Willey J., Paraskevopoulos T., Li Z., Palmer J.L., et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009, 115:2004-2012.
2. Breitbart W., Gibson C., Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 2002, 43:183-194.
3. Maltoni M., Caraceni A., Brunelli C., Broeckaert B., Christakis N., Eychmueller S., et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005, 23:6240-6248.
4. Scarpi E., Maltoni M., Miceli R., Mariani L., Caraceni A., Amadori D., et al. Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 2011, 16:1793-1799.
5. Pereira J., Hanson J., Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997, 79:835-842.
6. Institute NC. Dictionary of cancer terms.
7. Del Fabbro E., Dalal S., Bruera E. Symptom control in palliative care-Part III: Dyspnea and delirium. J Palliat Med 2006, 9:422-436.
8. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1980, American Psychiatric Association, Washington, DC. 3rd ed.
9. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1987, American Psychiatric Association, Washington, DC. revised 3rd ed.
10. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV-TR 2000, American Psychiatric Publishing Inc., Washington, DC.
11. Tucker G. The diagnosis of delirium and DSM-IV. Dement Geriatr Cogn Disord 1999, 10:359-363.
12. Greer N, Rossom R, Anderson P, MacDonald R, Tacklind J, Rutks I, et al. Delirium: screening, prevention, and diagnosis - a systematic review of the evidence 2011 [Internet].
13. Fang C.K., Chen H.W., Liu S.I., Lin C.J., Tsai L.Y., Lai Y.L. Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol 2008, 38:56-63.
14. Gaudreau J-D, Gagnon P, Roy M-A, Radtke FM. Delirium subtypes in hospitalized cancer patients: prevalence and evolution. In: IPOS 12th world congress of psycho-oncology, Quebec City, QC, Canada; 2010. p. s276.
15. Gaudreau J.D., Gagnon P., Harel F., Roy M.A., Tremblay A. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005, 23:6712-6718.
16. Gagnon P, Allard P, Gagnon B, Merette C, Jomphe V, Mond C, et al. Delirium phenomenology in terminal cancer. In: 11th World congress of psycho-oncology of the international psycho-oncology society (IPOS), Vienna, Austria; 2009. p. 18 (p. S300).
17. Weckmann M. Delirium incidence and cause in younger hospitalized patients with advanced cancer. J Pain Symptom Manage 2012, 43:470.
18. Lawlor P.G., Gagnon B., Mancini I.L., Pereira J.L., Hanson J., Suarez-Almazor M.E., et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000, 160:786-794.
19. Gagnon P., Allard P., Masse B., DeSerres M. Delirium in terminal cancer: a prospective study using daily screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 2000, 19:412-426.
20. Casarett D.J., Inouye S.K. Diagnosis and management of delirium near the end of life. Ann Intern Med 2001, 135:32-40.
21. Bond S.M., Dietrich M.S., Shuster J.L., Murphy B.A. Delirium in patients with head and neck cancer in the outpatient treatment setting. Support Care Cancer 2012, 20:1023-1030.
22. Wada T., Wada M., Onishi H. Characteristics, interventions, and outcomes of misdiagnosed delirium in cancer patients. Palliat Support Care 2010, 8:125-131.
23. Laurila J.V., Laakkonen M.L., Tilvis R.S., Pitkala K.H. Predisposing and precipitating factors for delirium in a frail geriatric population. J Psychosom Res 2008, 65:249-254.
24. Inouye S.K. Delirium in older persons. N Engl J Med 2006, 354:1157-1165.
25. White J., Hammond L. Delirium assessment tool for end of life: CHIMBOP. J Palliat Med 2008, 11:1069.
26. Hshieh T.T., Fong T.G., Marcantonio E.R., Inouye S.K. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A: Biol Sci Med Sci 2008, 63:764-772.
27. Cerejeira J., Firmino H., Vaz-Serra A., Mukaetova-Ladinska E.B. The neuroinflammatory hypothesis of delirium. Acta Neuropathol 2010, 119:737-754.
28. Cerejeira J., Nogueira V., Luis P., Vaz-Serra A., Mukaetova-Ladinska E.B. The cholinergic system and inflammation: common pathways in delirium pathophysiology. J Am Geriatr Soc 2012, 60:669-675.
29. Trzepacz P.T. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 2000, 5:132-148.
30. Steiner L.A. Postoperative delirium. Part 1: Pathophysiology and risk factors. Eur J Anaesthesiol 2011, 28:628-636.
31. Agar M., Lawlor P. Delirium in cancer patients: a focus on treatment-induced psychopathology. Curr Opin Oncol 2008, 20:360-366.
32. Gaudreau J.D., Gagnon P., Roy M.A., Harel F., Tremblay A. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 2007, 109:2365-2373.
33. Teeling J.L., Perry V.H. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158:1062-1073.
34. Garden G.A., Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006, 1:127-137.
35. van Gool W.A., van de Beek D., Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010, 375:773-775.
36. Kazmierski J., Kloszewska I. Is cortisol the key to the pathogenesis of delirium after coronary artery bypass graft surgery?. Crit Care 2011, 15:102.
37. Wong C.L., Holroyd-Leduc J., Simel D.L., Straus S.E. Does this patient have delirium?: value of bedside instruments. JAMA 2010, 304:779-786.
38. Bhat R., Rockwood K. Delirium as a disorder of consciousness. J Neurol Neurosurg Psychiatry 2007, 78:1167-1170.
39. Bosisio M., Caraceni A., Grassi L. Phenomenology of delirium in cancer patients, as described by the Memorial Delirium Assessment Scale (MDAS) and the Delirium Rating Scale (DRS). Psychosomatics 2006, 47:471-478.
40. Freedheim D.K. Handbook of psychology: history of psychology 2003, Wiley. D.K. Freedheim (Ed.).
41. Caraceni A., Simonetti F. Palliating delirium in patients with cancer. Lancet Oncol 2009, 10:164-172.
42. Gupta N., de Jonghe J., Schieveld J., Leonard M., Meagher D. Delirium phenomenology: what can we learn from the symptoms of delirium?. J Psychosom Res 2008, 65:215-222.
43. Meagher D.J., Moran M., Raju B., Gibbons D., Donnelly S., Saunders J., et al. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry 2007, 190:135-141.
44. Engel G.L., Romano J. Delirium, a syndrome of cerebral insufficiency (1959). J Neuropsychiatry Clin Neurosci 2004, 16:526-538.
45. Kamholz B. Update on delirium: diagnosis, management, and pathophysiology. Psychiatric Ann 2010, 40:52.
46. Trompeo A.C., Vidi Y., Locane M.D., Braghiroli A., Mascia L., Bosma K., et al. Sleep disturbances in the critically ill patients: role of delirium and sedative agents. Minerva Anestesiol 2011, 77:604-612.
47. Liptzin B., Levkoff S.E. An empirical study of delirium subtypes. Br J Psychiatry 1992, 161:843-845.
48. Meagher D., Moran M., Raju B., Leonard M., Donnelly S., Saunders J., et al. A new data-based motor subtype schema for delirium. J Neuropsychiatry Clin Neurosci 2008, 20:185-193.
49. Kaplan N.M., Palmer B.F., Roche V. Etiology and management of delirium. Am J Med Sci 2003, 325:20.
50. Peterson J.F., Pun B.T., Dittus R.S., Thomason J.W., Jackson J.C., Shintani A.K., et al. Delirium and its motoric subtypes: a study of 614 critically ill patients. J Am Geriatr Soc 2006, 54:479-484.
51. Stagno D., Gibson C., Breitbart W. The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response. Palliat Support Care 2004, 2:171-179.
52. Spiller J.A., Keen J.C. Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. Palliat Med 2006, 20:17-23.
53. Moyer D.D. Review article: terminal delirium in geriatric patients with cancer at end of life. Am J Hosp Palliat Care 2011, 28:44-51.
54. Meagher D. Motor subtypes of delirium: past, present and future. Int Rev Psychiatry 2009, 21:59-73.
55. Meagher D.J., Leonard M., Donnelly S., Conroy M., Adamis D., Trzepacz P.T. A longitudinal study of motor subtypes in delirium: frequency and stability during episodes. J Psychosom Res 2012, 72:236-241.
56. Kiely D.K., Jones R.N., Bergmann M.A., Marcantonio E.R. Association between psychomotor activity delirium subtypes and mortality among newly admitted post-acute facility patients. J Gerontol A: Biol Sci Med Sci 2007, 62:174-179.
57. Yang F.M., Marcantonio E.R., Inouye S.K., Kiely D.K., Rudolph J.L., Fearing M.A., et al. Phenomenological subtypes of delirium in older persons: patterns, prevalence, and prognosis. Psychosomatics 2009, 50:248-254.
58. Meagher D.J., Leonard M., Donnelly S., Conroy M., Adamis D., Trzepacz P.T. A longitudinal study of motor subtypes in delirium: relationship with other phenomenology, etiology, medication exposure and prognosis. J Psychosom Res 2011, 71:395-403.
59. Steis M.R., Fick D.M. Are nurses recognizing delirium? A systematic review. J Gerontol Nurs 2008, 34:40-48.
60. Somes J., Donatelli N.S., Barrett J. Sudden confusion and agitation: causes to investigate! Delirium, dementia, depression. J Emerg Nurs 2010, 36:486-488.
61. Sands M.B., Dantoc B.P., Hartshorn A., Ryan C.J., Lujic S. Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale. Palliat Med 2010, 24:561-565.
62. Larner A.J. Screening utility of the Montreal Cognitive Assessment (MoCA): in place of - or as well as - the MMSE?. Int Psychogeriatr 2012, 24:391-396.
63. Cole M.G., Dendukuri N., McCusker J., Han L. An empirical study of different diagnostic criteria for delirium among elderly medical inpatients. J Neuropsychiatry Clin Neurosci 2003, 15:200-207.
64. Kazmierski J., Kowman M., Banach M., Fendler W., Okonski P., Banys A., et al. The use of DSM-IV and ICD-10 criteria and diagnostic scales for delirium among cardiac surgery patients: results from the IPDACS study. J Neuropsychiatry Clin Neurosci 2010, 22:426-432.
65. Kazmierski J., Kowman M., Banach M., Fendler W., Okonski P., Banys A., et al. Clinical utility and use of DSM-IV and ICD-10 Criteria and The Memorial Delirium Assessment Scale in establishing a diagnosis of delirium after cardiac surgery. Psychosomatics 2008, 49:73-76.
66. Lawlor P.G., Nekolaichuk C., Gagnon B., Mancini I.L., Pereira J.L., Bruera E.D. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: assessing delirium in advanced cancer. Cancer 2000, 88:2859-2867.
67. Fadul N., Kaur G., Zhang T., Palmer J.L., Bruera E. Evaluation of the memorial delirium assessment scale (MDAS) for the screening of delirium by means of simulated cases by palliative care health professionals. Support Care Cancer 2007, 15:1271-1276.
68. Young J., Murthy L., Westby M., Akunne A., O'Mahony R. Diagnosis, prevention, and management of delirium: summary of NICE guidance. BMJ 2010, 341:c3704.
69. Levy M.H., Back A., Benedetti C., Billings J.A., Block S., Boston B., et al. NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw 2009, 7:436-473.
70. American Psychiatric Association Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999, 156:1-20.
71. Cole M.G., McCusker J., Bellavance F., Primeau F.J., Bailey R.F., Bonnycastle M.J., et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ 2002, 167:753-759.
72. Pitkala K.H., Laurila J.V., Strandberg T.E., Tilvis R.S. Multicomponent geriatric intervention for elderly inpatients with delirium: a randomized, controlled trial. J Gerontol A: Biol Sci Med Sci 2006, 61:176-181.
73. Breitbart W., Tremblay A., Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002, 43:175-182.
74. Boettger S., Friedlander M., Breitbart W., Passik S. Aripiprazole and haloperidol in the treatment of delirium. Aust NZ J Psychiatry 2011, 45:477-482.
75. Boettger S., Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care 2011, 9:351-357.
76. Gagnon B., Low G., Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005, 30:100-107.
77. Elie D., Gagnon P., Gagnon B., Giguere A. Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: a literature review. Can J Psychiatry 2010, 55:386-393.
78. Barcia E., Reyes R., Luz Azuara M., Sanchez Y., Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003, 11:107-113.
79. Hui D., Reddy A., Palla S., Bruera E. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care 2011, 27:141-147.
80. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007:CD005594.
81. Breitbart W., Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012, 30:1206-1214.
82. Administration UFaD. Information for healthcare professionals: haloperidol; 2007.
83. Meyer-Massetti C., Cheng C.M., Sharpe B.A., Meier C.R., Guglielmo B.J. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?. J Hosp Med 2010, 5:E8-E16.
84. Kim S.W., Yoo J.A., Lee S.Y., Kim S.Y., Bae K.Y., Yang S.J., et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 2010, 25:298-302.
85. Elsayem A., Bush S.H., Munsell M.F., Curry E., Calderon B.B., Paraskevopoulos T., et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manage 2010, 40:774-782.
86. Fainsinger R.L., Waller A., Bercovici M., Bengtson K., Landman W., Hosking M., et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000, 14:257-265.
87. Maltoni M., Scarpi E., Rosati M., Derni S., Fabbri L., Martini F., et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 2012, 30:1378-1383.
88. Breitbart W., Rosenfeld B., Roth A., Smith M.J., Cohen K., Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997, 13:128-137.
89. Inouye S.K., van Dyck C.H., Alessi C.A., Balkin S., Siegal A.P., Horwitz R.I. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990, 113:941-948.
90. Ryan K., Leonard M., Guerin S., Donnelly S., Conroy M., Meagher D. Validation of the confusion assessment method in the palliative care setting. Palliat Med 2009, 23:40-45.
91. Gaudreau J.D., Gagnon P., Harel F., Tremblay A., Roy M.A. Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage 2005, 29:368-375.
92. Adamis D., Sharma N., Whelan P.J., Macdonald A.J. Delirium scales: a review of current evidence. Aging Ment Health 2010, 14:543-555.
93. Grassi L., Caraceni A., Beltrami E., Borreani C., Zamorani M., Maltoni M., et al. Assessing delirium in cancer patients: the Italian versions of the Delirium Rating Scale and the Memorial Delirium Assessment Scale. J Pain Symptom Manage 2001, 21:59-68.
94. Marcantonio E.R., Palihnich K., Appleton P., Davis R.B. Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. J Am Geriatr Soc 2011, 59(Suppl. 2):S282-S288.
95. Tagarakis G.I., Voucharas C., Tsolaki F., Daskalopoulos M.E., Papaliagkas V., Parisis C., et al. Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. J Cardiothorac Surg 2012, 7:25.
96. Tahir T.A., Eeles E., Karapareddy V., Muthuvelu P., Chapple S., Phillips B., et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 2010, 69:485-490.
97. van Eijk M.M., Roes K.C., Honing M.L., Kuiper M.A., Karakus A., van der Jagt M., et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 2010, 376:1829-1837.
98. Devlin J.W., Roberts R.J., Fong J.J., Skrobik Y., Riker R.R., Hill N.S., et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010, 38:419-427.
99. Overshott R., Vernon M., Morris J., Burns A. Rivastigmine in the treatment of delirium in older people: a pilot study. Int Psychogeriatr 2010, 22:812-818.
100. Hu H., Deng W., Yang H., Liu Y. Olanzapine and haloperidol for senile delirium: a randomized controlled observation. Chin J Clin Rehab 2006, 10:188-190.
101. Breitbart W., Marotta R., Platt M.M., Weisman H., Derevenco M., Grau C., et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996, 153:231-237.
102. Grover S., Kumar V., Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. J Psychosom Res 2011, 71:277-281.
103. Han C.S., Kim Y.K. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004, 45:297-301.